Wednesday, September 18, 2013

Glivec Generics should enter Japan market early next year

Glivec Generics should enter Japan market early next year, as five companies have received approval for launching generic versions of Glivec in Japan. Novartis generates about Yen 38b ($380m)  in annual sales from Glivec in Japan.  Apart from Glivec, MHLW has also granted approval to Novartis' own generic subsidiary Sandoz for launching an authorized generic version of Diovan.  Sandoz may be the sole player in the market until June 2014, as Diovan patent expires in September 2013, and other generic players may not be in a position to file for the NHI listing in December. 

Enter your email address:


Delivered by FeedBurner